Advanced search
1 file | 112.50 KB Add to list

Increased canine pancreatic lipase immunoreactivity (cPLI) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6 '-methylresorufin) ester (DGGR) lipase in dogs with evidence of portal hypertension and normal pancreatic histology : a pilot study

Author
Organization
Abstract
The clinical presentations of both liver disease and pancreatitis are nonspecific and overlapping, which may cause difficulty in diagnosis. In our retrospective pilot study, we assessed whether dogs with evidence of portal hypertension and absence of pancreatitis on pancreatic histology have increases in canine pancreatic lipase immunoreactivity (cPLI) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6 '-methylresorufin) ester (DGGR) lipase. We included dogs that had been presented between 2008 and 2019 if they had normal pancreatic histology, histologically confirmed hepatopathy, and if canine pancreas-specific lipase (Spec cPL; Idexx) or DGGR lipase had been measured. Only dogs with portal hypertension were included. Six dogs fulfilled the inclusion criteria. Four of 6 and 2 of 6 dogs had Spec cPL and DGGR lipase exceeding the upper reference limit, respectively. From the 4 dogs with increased Spec cPL, 2 had concentrations of 200-400 mu g/L and 2 had concentrations >= 400 mu g/L. Our results suggest that canine portal hypertension might lead to increased Spec cPL and DGGR lipase values in the absence of pancreatitis on histology. Until more evidence in a larger number of dogs with portal hypertension is available, both tests should be interpreted cautiously in the presence of portal hypertension.
Keywords
cPLI (canine pancreatic lipase immunoreactivity), DGGR lipase, (1, 2-o-dilauryl-rac-glycero-3-glutaricacid-(6'-methylresorufin) ester), dogs, liver, MAPSS (multiple acquired portosystemic shunts), portal, hypertension, Spec cPL (canine pancreas-specific lipase).

Downloads

  • lipase10406387211003987.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 112.50 KB

Citation

Please use this url to cite or link to this publication:

MLA
Serrano, Goncalo, et al. “Increased Canine Pancreatic Lipase Immunoreactivity (CPLI) and 1,2-o-Dilauryl-Rac-Glycero-3-Glutaric Acid-(6 ’-Methylresorufin) Ester (DGGR) Lipase in Dogs with Evidence of Portal Hypertension and Normal Pancreatic Histology : A Pilot Study.” JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, vol. 33, no. 3, 2021, pp. 548–53, doi:10.1177/10406387211003987.
APA
Serrano, G., Paepe, D., Williams, T., & Watson, P. (2021). Increased canine pancreatic lipase immunoreactivity (cPLI) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6 ’-methylresorufin) ester (DGGR) lipase in dogs with evidence of portal hypertension and normal pancreatic histology : a pilot study. JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, 33(3), 548–553. https://doi.org/10.1177/10406387211003987
Chicago author-date
Serrano, Goncalo, Dominique Paepe, Tim Williams, and Penny Watson. 2021. “Increased Canine Pancreatic Lipase Immunoreactivity (CPLI) and 1,2-o-Dilauryl-Rac-Glycero-3-Glutaric Acid-(6 ’-Methylresorufin) Ester (DGGR) Lipase in Dogs with Evidence of Portal Hypertension and Normal Pancreatic Histology : A Pilot Study.” JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION 33 (3): 548–53. https://doi.org/10.1177/10406387211003987.
Chicago author-date (all authors)
Serrano, Goncalo, Dominique Paepe, Tim Williams, and Penny Watson. 2021. “Increased Canine Pancreatic Lipase Immunoreactivity (CPLI) and 1,2-o-Dilauryl-Rac-Glycero-3-Glutaric Acid-(6 ’-Methylresorufin) Ester (DGGR) Lipase in Dogs with Evidence of Portal Hypertension and Normal Pancreatic Histology : A Pilot Study.” JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION 33 (3): 548–553. doi:10.1177/10406387211003987.
Vancouver
1.
Serrano G, Paepe D, Williams T, Watson P. Increased canine pancreatic lipase immunoreactivity (cPLI) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6 ’-methylresorufin) ester (DGGR) lipase in dogs with evidence of portal hypertension and normal pancreatic histology : a pilot study. JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION. 2021;33(3):548–53.
IEEE
[1]
G. Serrano, D. Paepe, T. Williams, and P. Watson, “Increased canine pancreatic lipase immunoreactivity (cPLI) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6 ’-methylresorufin) ester (DGGR) lipase in dogs with evidence of portal hypertension and normal pancreatic histology : a pilot study,” JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, vol. 33, no. 3, pp. 548–553, 2021.
@article{8709205,
  abstract     = {{The clinical presentations of both liver disease and pancreatitis are nonspecific and overlapping, which may cause difficulty in diagnosis. In our retrospective pilot study, we assessed whether dogs with evidence of portal hypertension and absence of pancreatitis on pancreatic histology have increases in canine pancreatic lipase immunoreactivity (cPLI) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6 '-methylresorufin) ester (DGGR) lipase. We included dogs that had been presented between 2008 and 2019 if they had normal pancreatic histology, histologically confirmed hepatopathy, and if canine pancreas-specific lipase (Spec cPL; Idexx) or DGGR lipase had been measured. Only dogs with portal hypertension were included. Six dogs fulfilled the inclusion criteria. Four of 6 and 2 of 6 dogs had Spec cPL and DGGR lipase exceeding the upper reference limit, respectively. From the 4 dogs with increased Spec cPL, 2 had concentrations of 200-400 mu g/L and 2 had concentrations >= 400 mu g/L. Our results suggest that canine portal hypertension might lead to increased Spec cPL and DGGR lipase values in the absence of pancreatitis on histology. Until more evidence in a larger number of dogs with portal hypertension is available, both tests should be interpreted cautiously in the presence of portal hypertension.}},
  author       = {{Serrano, Goncalo and Paepe, Dominique and Williams, Tim and Watson, Penny}},
  issn         = {{1040-6387}},
  journal      = {{JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION}},
  keywords     = {{cPLI (canine pancreatic lipase immunoreactivity),DGGR lipase,(1,2-o-dilauryl-rac-glycero-3-glutaricacid-(6'-methylresorufin) ester),dogs,liver,MAPSS (multiple acquired portosystemic shunts),portal,hypertension,Spec cPL (canine pancreas-specific lipase).}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{548--553}},
  title        = {{Increased canine pancreatic lipase immunoreactivity (cPLI) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6 '-methylresorufin) ester (DGGR) lipase in dogs with evidence of portal hypertension and normal pancreatic histology : a pilot study}},
  url          = {{http://dx.doi.org/10.1177/10406387211003987}},
  volume       = {{33}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: